Free tool
FAERS Monitor: Duetact
Last checked: Nov 19, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 021925 or its brand name (Duetact, Glimepiride, Pioglitazone Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
93
Serious
48
52% of reports
Hospitalization
16
Death reported
8
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- blood glucose increased9
- bladder cancer8
- drug ineffective8
- dyspnoea7
- nausea7
- vomiting6
- depression5
- dizziness5
- flushing5
- malaise5
- anxiety4
- asthenia4
- cough4
- diarrhoea4
- oedema peripheral4
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2007 | 4 |
| 2008 | 14 |
| 2009 | 7 |
| 2010 | 5 |
| 2011 | 16 |
| 2012 | 4 |
| 2013 | 3 |
| 2014 | 2 |
| 2015 | 14 |
| 2016 | 7 |
| 2018 | 2 |
| 2019 | 4 |
| 2020 | 3 |
| 2021 | 1 |
| 2022 | 2 |
| 2023 | 3 |
| 2026 | 2 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,066 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| bladder cancerSignal | 8 | 30.7 | 15.8 | 202 |
| flushingSignal | 5 | 11.1 | 4.7 | 37 |
| blood glucose increasedSignal | 9 | 10.8 | 5.8 | 71 |
| oedema peripheralSignal | 4 | 7.4 | 2.8 | 16 |
| depressionSignal | 5 | 5.0 | 2.1 | 12 |
| coughSignal | 4 | 3.2 | 1.2 | 4 |
| anxietySignal | 4 | 3.2 | 1.2 | 4 |
| vomitingSignal | 6 | 2.9 | 1.3 | 6 |
| dyspnoeaSignal | 7 | 2.8 | 1.4 | 7 |
| malaise | 5 | 2.6 | 1.1 | 3 |
| asthenia | 4 | 2.4 | 0.9 | 2 |
| dizziness | 5 | 2.3 | 1.0 | 2 |
| nausea | 7 | 2.0 | 1.0 | 3 |
| diarrhoea | 4 | 1.4 | 0.5 | 0 |
| drug ineffective | 8 | 1.4 | 0.7 | 1 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.